List of Excipients in Branded Drug LUCEMYRA

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
US WorldMeds LLC	LUCEMYRA	lofexidine hydrochloride	27505-050	CALCIUM STEARATE
US WorldMeds LLC	LUCEMYRA	lofexidine hydrochloride	27505-050	CELLULOSE, MICROCRYSTALLINE
US WorldMeds LLC	LUCEMYRA	lofexidine hydrochloride	27505-050	CITRIC ACID MONOHYDRATE

LUCEMYRA Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: August 23, 2026

LUCEMYRA (lofexidine hydrochloride) is an immediate-release, film-coated tablet approved by the FDA on May 16, 2018, to mitigate opioid withdrawal symptoms in adults.[1] Its excipient system uses conventional direct-compression and film-coating materials rather than a proprietary delivery platform. The main commercial opportunity is therefore not a high-barrier excipient patent estate. It is the development of improved dosage forms, lower-cost generic equivalents, adherence-oriented regimens, and differentiated products for medically supervised opioid withdrawal.

The product has a relatively simple formulation, a short treatment duration, and a low dose per tablet. Those factors create opportunities in content-uniformity control, tablet robustness, coating efficiency, and reformulated products. They also limit the defensibility of a formulation strategy based only on standard excipients.

What is LUCEMYRA and how is it used?

LUCEMYRA contains lofexidine hydrochloride, an alpha-2 adrenergic receptor agonist that reduces sympathetic symptoms associated with opioid withdrawal. It is not an opioid and does not treat opioid use disorder itself.[1]

Attribute	LUCEMYRA profile
Active ingredient	Lofexidine hydrochloride
Strength	0.18 mg lofexidine per tablet
Dosage form	Immediate-release, film-coated tablet
FDA approval	May 16, 2018
Indication	Mitigation of opioid withdrawal symptoms in adults
Typical dosing	Three 0.18 mg tablets four times daily, adjusted by tolerability
Maximum daily dose	16 tablets, or 2.88 mg lofexidine, per day
Maximum treatment period in labeling	14 days
Administration	Oral
Product category	Small-molecule prescription drug
Biosimilar pathway	Not applicable

The dosing burden is commercially important. Patients can take multiple tablets per day, while treatment is generally limited to a short withdrawal period. A product that reduces pill burden without materially increasing hypotension, bradycardia, or QT-related risk could have stronger clinical and commercial differentiation than a standard generic tablet.[1]

What excipients are used in LUCEMYRA tablets?

The FDA-approved product uses a conventional tablet core and film coat. The listed inactive ingredients include microcrystalline cellulose, lactose-related excipients, pregelatinized starch, crospovidone, colloidal silicon dioxide, and magnesium stearate. The film coating contains standard coating components, including hypromellose, titanium dioxide, and plasticizing or pigment materials identified in the approved labeling.[2]

Functional role of the principal excipients

Excipient category	Likely formulation function	Commercial relevance
Microcrystalline cellulose	Filler and dry-binder	Supports tablet strength and direct compression
Lactose	Filler and bulking agent	Low-cost, widely available, but relevant to lactose-sensitive positioning
Pregelatinized starch	Binder and disintegrant	Improves compactability and tablet breakup
Crospovidone	Superdisintegrant	Supports rapid disintegration in an immediate-release product
Colloidal silicon dioxide	Glidant and moisture-flow aid	Helps powder flow and content uniformity
Magnesium stearate	Lubricant	Controls ejection force but can impair dissolution if over-lubricated
Hypromellose	Film-forming polymer	Provides coating integrity and swallowability
Titanium dioxide and colorants	Opacity and product identification	Supports tablet identification and brand appearance

The formulation challenge is the 0.18 mg dose. The active ingredient represents a small fraction of tablet mass, so blend uniformity, segregation control, and sampling strategy are more important than raw material cost. A generic manufacturer would need to demonstrate pharmaceutical equivalence and bioequivalence while controlling active-content distribution across the batch.

How does the excipient strategy affect generic manufacturing?

A generic LUCEMYRA tablet should be technically accessible because the reference product does not depend on a complex modified-release matrix, liposomal system, transdermal delivery platform, or biologic formulation.

The main development risks are:

1. Low-dose blend uniformity.
2. Tablet weight and hardness consistency.
3. Rapid but reproducible disintegration.
4. Dissolution matching across the relevant pH range.
5. Film-coat consistency and appearance.
6. Magnesium stearate over-lubrication.
7. Stability under moisture and temperature stress.
8. Comparable impurity and degradation profiles.

The use of common excipients reduces sourcing risk. Manufacturers can qualify multiple suppliers for microcrystalline cellulose, lactose, starch, crospovidone, silica, magnesium stearate, and coating polymers. That creates procurement leverage and reduces dependence on a single proprietary excipient supplier.

A co-processed excipient platform could simplify manufacturing by combining filler, binder, and disintegrant functions. Examples include silicified microcrystalline cellulose, co-processed cellulose-starch systems, and directly compressible lactose blends. Such systems may improve flow and reduce unit operations, but they would not automatically create meaningful patent protection. The manufacturer would need to show a measurable performance advantage, such as improved content uniformity, lower friability, faster scale-up, or better stability.

What formulation improvements could create commercial opportunities?

The strongest opportunities are products that address dosing burden, patient tolerability, excipient restrictions, or administration outside conventional pharmacy settings.

Lower-pill-burden formulations

The approved regimen can require several tablets per day. A higher-strength tablet, bilayer tablet, multiparticulate capsule, or modified-release product could reduce administration frequency. The clinical risk is that lofexidine dosing is titrated according to withdrawal symptoms and tolerability. A sustained-release product may increase exposure during periods when hypotension or bradycardia is clinically significant.

A once-daily or twice-daily formulation would require pharmacokinetic and clinical validation. Its commercial value would depend on proving that adherence gains outweigh the safety and development costs.

Orally disintegrating tablets

An orally disintegrating tablet could support supervised withdrawal treatment in detoxification facilities, emergency departments, correctional health systems, and other settings where water access or swallowing ability is limited. The opportunity is technically plausible because the product is an immediate-release tablet.

The main formulation barriers would include taste, friability, moisture sensitivity, packaging, and dose uniformity. Lofexidine taste-masking could require polymer coating, ion-exchange resin complexation, or flavor systems. Each approach adds development complexity and may affect dissolution.

Lactose-free or reduced-allergen positioning

A lactose-free version could address patients or institutions that avoid lactose-containing products. That opportunity is commercially narrower than a pill-burden reduction strategy because the amount of lactose in a small tablet may be clinically insignificant for many patients. It could still provide procurement value for hospital formularies with excipient restrictions.

Possible substitutes include mannitol, dibasic calcium phosphate, anhydrous dibasic calcium phosphate, or alternative grades of microcrystalline cellulose. Substitution would require renewed assessment of hardness, disintegration, dissolution, hygroscopicity, and stability.

Abuse-deterrent or tamper-evident formats

Lofexidine is not an opioid and is not intended to produce opioid euphoria. A formal abuse-deterrent platform would therefore have a weak commercial rationale compared with opioid analgesics. Packaging that supports adherence, dose tracking, or supervised administration is more commercially defensible than an abuse-deterrent tablet.

Combination or sequential-treatment products

Lofexidine may be used during opioid withdrawal alongside behavioral treatment and, in some clinical pathways, before transition to medication for opioid use disorder. A co-packaged withdrawal regimen could combine lofexidine with counseling materials, monitoring tools, or separately prescribed maintenance therapy. A fixed-dose combination would face clinical, regulatory, and intellectual-property barriers because the treatment sequence is individualized.

What patents protect LUCEMYRA and its formulation?

LUCEMYRA is protected primarily through patents covering lofexidine, its pharmaceutical compositions, and methods of treating opioid withdrawal. The exact scope and expiration of listed patents must be determined from the current FDA Orange Book and relevant USPTO records because patent listings, terminal disclaimers, pediatric extensions, and expiration calculations can change the practical entry date.[3,4]

The principal patent categories are:

Patent category	Potential subject matter	Relevance to excipient strategy
Active-ingredient patents	Lofexidine compounds or salts	Can block use of the active ingredient before expiration
Composition patents	Tablets or pharmaceutical compositions containing lofexidine	May cover broad or narrow excipient combinations
Method-of-use patents	Treatment or mitigation of opioid withdrawal	Can affect labeled generic use and carve-out strategy
Process patents	Manufacturing, purification, or crystallization	May create production barriers without blocking all formulations
Formulation patents	Release profile, dosage strength, or administration route	Most relevant to lifecycle products
Packaging or adherence patents	Dose administration and treatment support	Usually narrower commercial protection

For a generic applicant, the central question is whether a listed patent claims the specific reference product, the active ingredient, the approved indication, or only a particular formulation. A patent that claims a broad composition may create more risk than a narrow patent limited to a specific excipient ratio or manufacturing process.

When does LUCEMYRA lose exclusivity?

LUCEMYRA received FDA approval in 2018. Statutory regulatory exclusivity for a small-molecule product depends on the FDA’s designation at approval and can differ from patent exclusivity. A five-year new chemical entity period, if applicable, would have expired in 2023, subject to any qualifying pediatric extension.[1,5]

Patent expiry is a separate issue. Generic entry may occur after regulatory exclusivity ends only if:

• No unexpired patent blocks the proposed product.
• A generic applicant successfully certifies against listed patents.
• Litigation does not result in an injunction or delayed launch.
• The applicant satisfies FDA requirements for an ANDA.

The FDA Orange Book remains the controlling public source for listed patents and regulatory exclusivity. Commercial diligence should distinguish the earliest possible ANDA approval date from the earliest practical launch date.

What is the Orange Book status of LUCEMYRA?

LUCEMYRA is an FDA-approved small-molecule prescription product that may be subject to Orange Book-listed patents and exclusivity information. Generic competition would proceed through the ANDA pathway rather than the biosimilar pathway.[3]

An ANDA applicant can submit:

• A Paragraph I certification if no relevant patent information is listed.
• A Paragraph II certification if the patent has expired.
• A Paragraph III certification with a proposed launch after patent expiry.
• A Paragraph IV certification asserting that a listed patent is invalid, unenforceable, or not infringed.

A Paragraph IV filing can trigger patent litigation if the patent holder sues within the statutory period. The commercial impact depends on the patent claims, litigation venue, settlement terms, and whether the applicant receives first-filer status.

Which companies are challenging LUCEMYRA exclusivity?

Public competition should be assessed through FDA ANDA approvals, tentative approvals, Paragraph IV litigation records, and Abbreviated New Drug Application litigation filings. The relevant potential challengers are generic pharmaceutical manufacturers with capabilities in low-dose immediate-release tablets, including large U.S. generic companies and contract development and manufacturing organizations.

No biosimilar companies are relevant because lofexidine is a small molecule. No reliable public source establishes a complete list of active commercial challengers without reviewing current FDA, court, and Orange Book records.[3,6]

The most likely competitive sequence is:

1. Patent and exclusivity review by generic applicants.
2. ANDA filing with Paragraph III or Paragraph IV certification.
3. Patent litigation if a Paragraph IV notice is served.
4. Potential settlement or authorized-generic arrangement.
5. Commercial entry after approval and any applicable stay or injunction.
6. Price erosion driven by the number of approved suppliers.

How strong is the LUCEMYRA patent estate?

The formulation estate appears less structurally defensible than the active-ingredient and method-of-use estate because the product uses standard immediate-release tablet technology. A generic manufacturer could likely develop around individual excipient claims unless a listed composition patent is drafted broadly enough to cover common alternatives.

Patent-strength assessment

Factor	Assessment
Active ingredient	Potentially stronger if unexpired composition or salt claims remain
Immediate-release tablet	Moderate to weak formulation barrier where standard excipients are used
Low-dose manufacturing	Practical manufacturing challenge, but not necessarily a patent barrier
Method of use	Potentially important for labeled opioid-withdrawal indications
Modified release	Opportunity for new patents, but requires new clinical evidence
Excipient substitution	Likely route for design-around if claims are narrow
Biosimilar protection	Not relevant
Generic pathway	ANDA, subject to Orange Book patents and exclusivity

The key diligence question is not whether LUCEMYRA has patents. It is whether the remaining claims cover a generic applicant’s active ingredient, dosage form, indication, or manufacturing process.

What licensing deals and partnerships could support LUCEMYRA growth?

Commercial opportunities exist for licensing outside the United States, formulation development, and institutional distribution. Potential counterparties include:

• Regional pharmaceutical companies with addiction-treatment portfolios.
• Generic manufacturers seeking authorized-generic or supply arrangements.
• CDMOs with low-dose tablet and film-coating expertise.
• Digital therapeutics companies supporting withdrawal monitoring.
• Hospital and correctional-health distributors.
• Specialty pharmacies serving addiction-treatment programs.

An excipient supplier could pursue a preferred-supplier agreement tied to a reformulated LUCEMYRA product. The strongest negotiating position would come from a demonstrable benefit, such as improved content uniformity, a lactose-free composition, lower tablet count, or simplified manufacturing.

Licensing a standard excipient alone would have limited value. A more defensible deal would combine a proprietary excipient system with formulation know-how, scale-up data, stability data, and patent claims directed to a specific performance advantage.

What FDA regulatory pathway applies to LUCEMYRA reformulations?

A conventional generic immediate-release tablet would generally use the ANDA pathway if it matches the reference product in active ingredient, dosage form, strength, route, labeling requirements, and bioequivalence.[7]

A reformulated product may require a different pathway:

Product concept	Likely regulatory route
Same 0.18 mg immediate-release tablet	ANDA
Lactose-free generic with equivalent performance	Usually ANDA if sameness and bioequivalence requirements are met
Orally disintegrating tablet	ANDA or 505(b)(2), depending on differences and FDA requirements
Higher-strength tablet	Potentially 505(b)(2) or NDA-supported development
Extended-release formulation	Usually 505(b)(2) or full NDA development
New indication	505(b)(2) or supplemental NDA
Combination product	NDA or 505(b)(2), depending on the product and evidence

A 505(b)(2) strategy may provide more flexibility for a new delivery system but requires a larger evidence package and may face additional patent certifications.

What revenue exposure and market opportunities exist?

LUCEMYRA revenue is not reliably disclosed as a standalone public metric in the FDA materials. The commercial market is tied to opioid withdrawal treatment, detoxification, emergency care, residential treatment, and institutional health systems rather than chronic daily prescribing.

Revenue opportunities divide into four segments:

1. Branded product sales before substantial generic entry.
2. Authorized-generic or licensed supply.
3. Lower-cost generic tablets after patent and exclusivity barriers decline.
4. Reformulated products with lower pill burden or administration advantages.

The short treatment duration limits lifetime value per patient. The high daily tablet count can support premium pricing for a better-adhered regimen, but only if the reformulation demonstrates clinically acceptable exposure and safety.

What generic launch scenarios exist for LUCEMYRA?

Scenario 1: Standard immediate-release generic entry

This is the most direct competitive threat. A manufacturer reproduces the 0.18 mg tablet using conventional excipients and competes primarily on price, supply reliability, and formulary access.

Scenario 2: Authorized generic or settlement entry

The brand owner may preserve channel access through an authorized generic or negotiate a later-entry settlement with a Paragraph IV challenger. The commercial effect would depend on the number of entrants and the timing of any authorized-generic launch.

Scenario 3: Reformulated branded product

A higher-strength, orally disintegrating, lactose-free, or modified-release product could extend the commercial lifecycle. It would need a clear clinical or operational advantage because the existing tablet is simple to manufacture.

Scenario 4: Institutional and specialty-channel competition

A supplier could target detoxification centers, hospitals, correctional systems, and specialty pharmacies with unit-dose packaging, adherence services, and bulk procurement pricing. This strategy may generate share without requiring a major formulation change.

How does LUCEMYRA compare with other opioid-withdrawal treatments?

Product or approach	Main mechanism or role	Excipient and IP opportunity
LUCEMYRA	Alpha-2 adrenergic agonist for withdrawal symptoms	Low-dose tablet, adherence, ODT, modified release
Clonidine	Alpha-2 adrenergic agonist used off-label for withdrawal	Broad generic availability; limited product differentiation
Buprenorphine	Medication for opioid use disorder and withdrawal management	Stronger commercial ecosystem, different regulatory and diversion considerations
Methadone	Opioid agonist used in structured treatment	Highly regulated distribution and established generic supply
Symptomatic OTC treatment	Addresses individual symptoms	Low-cost, fragmented competition

LUCEMYRA’s differentiator is its FDA-approved indication for mitigation of opioid withdrawal symptoms without being an opioid. Its weaknesses are short treatment duration, frequent dosing, cardiovascular tolerability constraints, and the absence of a complex formulation barrier.

Key Takeaways

• LUCEMYRA is a 0.18 mg immediate-release lofexidine tablet approved in 2018.
• Its excipient system is conventional and includes cellulose, lactose-related fillers, starch, crospovidone, silica, magnesium stearate, and film-coating materials.
• The main formulation challenge is low-dose content uniformity, not a sophisticated delivery technology.
• The strongest commercial opportunities are reduced pill burden, orally disintegrating delivery, lactose-free formulations, adherence packaging, and institutional distribution.
• LUCEMYRA faces small-molecule generic risk through the ANDA pathway, not biosimilar competition.
• Patent strength depends on the current Orange Book claims covering lofexidine, compositions, methods of use, and manufacturing.
• Standard excipient substitution may support design-around, but a commercially valuable reformulation requires clinical or manufacturing advantages.
• Revenue potential is concentrated in short-course withdrawal treatment, specialty channels, detoxification facilities, hospitals, and correctional health systems.

FAQs

Can a lactose-free LUCEMYRA generic be developed?

Yes. Lactose can potentially be replaced with mannitol, calcium phosphate, or an alternative cellulose-based filler. The manufacturer would need to match tablet performance, dissolution, stability, and bioequivalence requirements.

Would an orally disintegrating lofexidine tablet qualify for an ANDA?

It may, but the answer depends on whether the dosage form and labeling differences meet FDA requirements for an ANDA. A materially different dosage form or clinical profile could require a 505(b)(2) application.

Is lofexidine subject to the FDA biosimilar pathway?

No. Lofexidine is a chemically synthesized small molecule. Generic competition would generally proceed through an ANDA.

Can an excipient supplier obtain patent protection around a LUCEMYRA reformulation?

Yes, if the reformulation produces a novel and non-obvious composition or measurable performance benefit. A patent based only on replacing one routine filler with another would face greater validity and commercial-enforcement risk.

What is the most attractive lifecycle-management strategy for LUCEMYRA?

A lower-frequency dosage form is the most commercially significant opportunity, but it also carries the highest clinical-development burden. A lactose-free or orally disintegrating tablet is easier to position technically, while adherence packaging and institutional supply can generate nearer-term channel value.

References

1. U.S. Food and Drug Administration. (2018). LUCEMYRA (lofexidine hydrochloride) prescribing information.
2. DailyMed. (n.d.). LUCEMYRA- lofexidine hydrochloride tablet, film coated. National Library of Medicine.
3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
4. United States Patent and Trademark Office. (n.d.). Patent Center and patent term information.
5. U.S. Food and Drug Administration. (n.d.). Small business assistance: Frequently asked questions on the regulatory exclusivity provisions.
6. U.S. Courts. (n.d.). PACER case locator and federal patent litigation records.
7. U.S. Food and Drug Administration. (2023). ANDA submissions: Content and format of abbreviated new drug applications.